Advertisement
U.S. markets closed

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.86-0.39 (-2.40%)
At close: 04:00PM EST
15.86 0.00 (0.00%)
After hours: 05:20PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close16.25
Open16.12
Bid15.82 x 800
Ask15.86 x 800
Day's Range15.32 - 16.26
52 Week Range3.94 - 17.42
Volume210,568
Avg. Volume462,813
Market Cap790.126M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-3.57
Earnings DateMar 07, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALXO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ALX Oncology Holdings Inc.
    Daily – Vickers Top Buyers & Sellers for 12/06/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced today that Jason Lettmann, Chief Executive Officer of ALX Oncology, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024. Mr. Lettmann’s presentation will take place on Mond

  • InvestorPlace

    7 Small-Cap Stocks That Wall Street Loves for Good Reason

    As we head into 2024, it’s common for investors to look back on 2023. Much of this year had investors in a defensive posture. Small-cap stocks lagged sharply behind the broader market. However, the market rally that started in November is showing signs of broadening to include small-cap stocks. But which ones are ready to shine in 2024? One place for you to start your research is in the stocks that are receiving upgrades from analysts. The market is forward-looking, and analysts are a significan

  • GuruFocus.com

    ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments

    Positive Clinical Trial Results and Public Offering Highlight the Quarter